Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

The slightly greater dose density of both chemotherapeutic agents in the cisplatin + fluorouracil regimen in women with respect to men does not appear sufficient to account for an overall trend toward greater response benefit of chemotherapy in men that, as we will see later and as previously reported, does not translate into a survival benefit. 42 This lower ORR in females may have to do with a higher percentage of diffuse cancers that are less chemosensitive.

also in 4,871 other papers